What are ADC's

Our services

ADC Review
is made possible by:

NCT01134575 (Clinical Trial / inotuzumab ozogamycin / CMC-544)

Study Title
CMC-544 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL) (NCT01134575)

Trial Description
The goal of this clinical research study is to learn if CMC-544 (Inotuzumab Ozogamycin) given alone, and possibly given in combination with rituximab, can help to control the disease in patients with ALL. The safety of the study drug(s) will also be studied.

This trial is sponsored by M.D. Anderson Cancer Center/ Pfitzer [1]

Study Data

  • Condition: Leukemia
  • Interventions:
  • Phase: I
  • Estimated Enrollment: 90
  • Start: June 2010
  • Estimated Primary Completion: June 2017
  • Last verified: April 2105

Study Schematic 

NCT01134575 (Clinical Trial / inotuzumab ozogamycin / CMC-544)

Click here to Return to Drug map

Last Editorial review: July 31, 2016
Information based on (NIH/NCI) and other sources.

Copyright © 2015-2016 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...

Skip to toolbar